Metastases: Clinical Trials

17 trials for Metastases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 17 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 317Completed 13, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1

Follow Metastases: new trials by email Literature Review of Metastases trials Research Report on Metastases

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
Sintilimab, Lenvatinib, Comprehensive Local Consolidative Therapy - Hepatocellular Carcinoma (HCC), Metastases
Phase 3Not yet recruitingTongji Hospital4002026-05-302026-04-17
S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.
Capecitabine, Teysuno, Bevacizumab - Colorectal Cancer, Metastases
Phase 3CompletedDutch Colorectal Cancer Group1612013-12-012018-03-14
Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.
Leuprorelin Acetate - Metastases
Phase 3Active not recruitingUNICANCER7002011-07-012024-09-19
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
AMG 479, Placebo, gemcitabine - Adenocarcinoma of the Pancreas, Advanced Solid Tumors
Phase 3CompletedNantCell, Inc.8002011-04-072024-07-16
Surgery and Whole Brain Radiotherapy (RT) Versus Whole Brain Radiotherapy (RT) and Radiosurgery for 1-3 Resectable Brain Metastases
surgery, radiosurgery - Metastases, Cancer
Phase 3WithdrawnBarretos Cancer Hospital2010-07-012014-02-04
Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
vinflunine, Alkylating agent of physician choice registered in cancer - Breast Cancer, Metastases
Phase 3CompletedPierre Fabre Medicament5942009-07-012019-09-16
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
Xaliproden (SR57746A), Placebo, Oxaliplatin - Metastases, Colorectal Neoplasms
Phase 3CompletedSanofi8792005-12-012016-05-04
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
MDX-010 (anti-CTLA4) monoclonal antibody, MDX-1379 (gp100) Melanoma Peptide Vaccine - Melanoma, Metastases
Phase 3CompletedBristol-Myers Squibb17832004-09-012011-07-11
DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer
YMB 1002 - Breast Cancer, Metastases
Phase 3TerminatedYM BioSciences7002004-05-012007-02-28
Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer
larotaxel (RPR109881, XRP9881), capecitabine - Breast Cancer, Metastases
Phase 3CompletedSanofi4382004-04-012008-08-21
Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast Cancer
Efaproxiral, Whole Brain Radiation Therapy (WBRT), Supplemental Oxygen - Breast Cancer, Metastases
Phase 3CompletedSpectrum Pharmaceuticals, Inc3682004-02-012013-05-10
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Best supportive care, Panitumumab - Colorectal Cancer, Metastases
Phase 3CompletedAmgen4632004-01-012022-11-07
Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Ixabepilone + Capecitabine, Capecitabine - Breast Cancer, Metastases
Phase 3CompletedR-Pharm7522003-09-012020-11-02
Phase III Trial of DP Followed by FOLFIRI or the Reverse Sequence in Unresectable Gastric Cancer
DP, FOLFIRI - Gastric Cancer, Metastases
Phase 3CompletedSamsung Medical Center2002003-05-012012-01-12
A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
Avastin (bevacizumab) - Breast Cancer, Colorectal Cancer
Phase 3CompletedGenentech, Inc.1002002-10-012014-03-26
XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy
SR57746A - Metastases, Colorectal Neoplasms
Phase 3CompletedSanofi6202002-07-012006-09-13
Iressa Expanded Access Program (EAP)
ZD1839 (Gefitinib) - Carcinoma, Non-small-cell Lung
Phase 3CompletedAstraZeneca2000-08-012013-01-04

Narrower conditions

Neoplasm Metastasis (17)  ·  Breast Neoplasms (6)  ·  Colorectal Neoplasms (5)  ·  Neoplasms (4)  ·  Brain Neoplasms (2)  ·  Neurotoxicity Syndromes (2)  ·  Paresthesia (2)  ·  Carcinoma (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Endocrine Gland Neoplasms (1)  ·  Hand-Foot Syndrome (1)  ·  Jaundice (1)  ·  Melanoma (1)  ·  Pancreatic Neoplasms (1)

Broader conditions

Neoplastic Processes (17)  ·  Pathologic Processes (17)  ·  Pathological Conditions, Signs and Symptoms (17)  ·  Neoplasms by Site (16)  ·  Neoplasms (13)  ·  Digestive System Diseases (8)  ·  Digestive System Neoplasms (8)  ·  Skin Diseases (8)  ·  Skin and Connective Tissue Diseases (8)  ·  Breast Diseases (6)  ·  Gastrointestinal Diseases (6)  ·  Gastrointestinal Neoplasms (6)  ·  Colonic Diseases (5)  ·  Intestinal Diseases (5)  ·  Intestinal Neoplasms (5)

Interventions

Capecitabine (3)  ·  Bevacizumab (2)  ·  xaliproden (2)  ·  Antibodies, Monoclonal (1)  ·  Epothilones (1)  ·  Fluorouracil (1)  ·  Gefitinib (1)  ·  Gemcitabine (1)  ·  IFL protocol (1)  ·  Ipilimumab (1)  ·  Leucovorin (1)  ·  Leuprolide (1)  ·  Neurosurgical Procedures (1)  ·  Oxaliplatin (1)  ·  Panitumumab (1)

Sponsors

Sanofi (3)  ·  Amgen (1)  ·  AstraZeneca (1)  ·  Barretos Cancer Hospital (1)  ·  Bristol-Myers Squibb (1)  ·  Dutch Colorectal Cancer Group (1)  ·  Genentech, Inc. (1)  ·  NantCell, Inc. (1)  ·  Pierre Fabre Medicament (1)  ·  R-Pharm (1)  ·  Samsung Medical Center (1)  ·  Spectrum Pharmaceuticals, Inc (1)  ·  Tongji Hospital (1)  ·  UNICANCER (1)  ·  YM BioSciences (1)

Countries

United Kingdom (8)  ·  Brazil (7)  ·  France (7)  ·  United States (7)  ·  Argentina (6)  ·  Canada (6)  ·  Germany (6)  ·  Hungary (6)  ·  Italy (6)  ·  Spain (6)  ·  Austria (4)  ·  Belgium (4)  ·  Chile (4)  ·  Poland (4)  ·  Portugal (4)

Top investigators

Cornelis JA Punt, Prof MD PhD (1)  ·  John Suh, MD (1)  ·  Karim Keddad, MD, PhD (1)  ·  Kathleen Pritchard, MD (1)  ·  Ricardo A Nakamura, MD (1)  ·  Stephane Culine, Prof, MD (1)  ·  Won Ki Kang, MD (1)

Results publications

PMID 30679026, PMID 31378656, PMID 36606664, PMID 17968020, PMID 18316791, PMID 20525992, PMID 21128114, PMID 21937232, PMID 22694829, PMID 23400564, PMID 23444228, PMID 23625191, PMID 23942774, PMID 24472478, PMID 25214238, PMID 25649350, PMID 25667295, PMID 26049686, PMID 26627641, PMID 26700304, PMID 28383633, PMID 29481630, PMID 29627309, PMID 30782413, PMID 34213592, PMID 37596461